Purine modulation of cytokine release during diuretic therapy of rheumatoid arthritis

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1107-1110

  Forrest, C M ^a   Harman, G ^b   McMillan, R B ^a   Rana, C ^a   Shaw, S ^b   Stone, T W ^a   Stoy, N ^b   Darlington, L G ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b EPSOM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Adenosine receptors; Bumetanide; Cytokines; Free radicals; Rheumatoid arthritis; Uric acid

Indexed keywords

ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR; BUMETANIDE; DIURETIC AGENT; FREE RADICAL; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; URIC ACID;

ADULT; AGED; BLOOD CULTURE; BLOOD SAMPLING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ACTIVITY; DIURETIC THERAPY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERURICEMIA; LIPID PEROXIDATION; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PURINE METABOLISM; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; ARTHRITIS, RHEUMATOID; BUMETANIDE; CYTOKINES; FREE RADICAL SCAVENGERS; FREE RADICALS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LIPID METABOLISM; LIPOPOLYSACCHARIDES; MIDDLE AGED; PLACEBOS; PURINES; RECEPTORS, PURINERGIC P1; TUMOR NECROSIS FACTOR-ALPHA; URIC ACID;

EID: 10344258605     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027369     Document Type: Conference Paper

References (9)

1. Becker, B.F. Towards the physiological function of uric acid. Free Rad. Biol. Med. 1993, 14, 615-631.
2. Arnett, F.C.; Edworth, S.M.; Block, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Lethra, H.S.; Medsgar, T.A.; Mitchell, D.M.; Neustadt, D.H.; Finals, R.S.; Schaller, J.G.; Sharp, J.T.; Wilder, R.L.; Hunder, G.G. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31, 315-324.
3. Agudelo, C.A.; Turner, R.A.; Panetti, M.; Pisko, E. Does hyperuricaemia protect from rheumatoid inflammation? A clinical study. Arthritis Rheum. 1984, 27, 443-448.
4. Situnayake, R.D.; Thurnham, D.I.; Kootathep, S.; Chirico, S.; Lunec, J.; Davis, M.; McConkey, B. Chain-breaking antioxidant status in rheumatoid arthritis: clinical and laboratory correlates. Ann. Rheum. Dis. 1991, 50, 81-86.
5. Deaney, C.L.; Feyi, K.; Forrest, C.M.; Freeman, A.; Harman, G.; Mcdonald, M.S.; Petrie, A.; Shaw, S.J.; Stone, T.W.; Stoy, N.; Darlington, L.G. Levels of lipid peroxidation products in an inflammatory disorder. Res. Commun. Mol. Pathol. Pharmacol. 2001, 110, 87-95.
6. Darlington, L.G. Study to compare the relative hyperuricaemic effects of fusemide and bumetanide. Adv. Exp. Med. Biol. 1986, 195, 333-339.
7. Yamamoto, T.; Moriwaki, Y.; Takahashi, S.; Tsutsumi, Z.; Hada, T. Effects of frusemide on renal excretion of oxypurinol and purine bases. Metab. Clin. Exp. 2001, 50, 241-245.
8. Revan, S.; Montesinos, M.C.; Naime, D.; Landau, S.; Cronstein, B.N. Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 1996, 271, 17114-17118.
9. Cronstein, B.N.; Bouma, M.G.; Becker, B.F. Purinergic mechanisms in inflammation. Drug Develop. Res. 1996, 39, 426-435.